Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE, Inc. (BIOL) generates frequent news as a medical device company focused on dental laser systems for dentistry and medicine. Company announcements describe BIOLASE as a global or globally recognized leader in dental laser technology, with principal products that include dental laser systems used for cosmetic and complex surgical procedures and related consumables such as disposable tips. News coverage often highlights how its laser platforms aim to provide less pain and faster recovery times for patients, while supporting a wide range of dental disciplines.
Investors and dental professionals following BIOLASE news will see updates on product launches, clinical education initiatives, financial performance, capital markets developments, and corporate restructuring events. Recent releases have covered the launch of the Waterlase iPlus Premier Edition all‑tissue laser system, featuring modular software design, enhanced user interface, on‑board animations, and Wi‑Fi‑enabled remote diagnostics. BIOLASE news also includes information on educational programs such as the “Let’s Talk Dental” webinar series and the Waterlase and Epic Diode academies, which address topics across restorative dentistry, periodontics, endodontics, pediatric dentistry, dental hygiene, and practice management.
Financial and corporate news items provide detail on quarterly and full‑year results, trends in laser and consumables revenue, gross margin, operating expenses, and the use of non‑GAAP measures such as Adjusted EBITDA. In 2024, BIOLASE announced its delisting from The Nasdaq Stock Market and subsequent trading on OTC Markets, as well as voluntary Chapter 11 proceedings and a proposed sale of substantially all assets to Sonendo Inc. For users tracking BIOL stock and BIOLASE developments, this news page offers a centralized view of the company’s operational updates, product milestones, financial disclosures, and restructuring process over time.
BIOLASE, Inc. (NASDAQ: BIOL) announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million after an $18 million Rights Offering. Nasdaq granted an additional 180-day grace period for the company to meet the $1.00 minimum bid price requirement, expiring on February 16, 2021. CFO John Beaver has been promoted to Chief Operating Officer, maintaining his financial duties. The company's laser systems support safe dental practices amid the COVID-19 pandemic, producing 98% less aerosols than traditional methods.
BIOLASE, Inc. (NASDAQ: BIOL) reported a significant 66% decline in net revenue for Q2 2020, totaling $2.9 million compared to $8.6 million in Q2 2019. U.S. laser revenue dropped 72%, and international sales fell 86%. Despite these challenges, the company highlights investor confidence through an oversubscribed rights offering, generating $15.8 million. Operating loss increased to $4.0 million, while net loss was $4.7 million, or $0.12 per share. BIOLASE aims to leverage its COVID-compliant products as dental practices resume normal operations.
BIOLASE, Inc. (NASDAQ: BIOL) will release its Q2 2020 financial results on August 13, 2020, after market close. The company will also host a conference call at 4:30 p.m. ET to discuss these results. For U.S./Canada participants, the dial-in number is 800-367-2403, while international participants can call 334-777-6978, using Conference ID 9516164. An audio archive of the call will be available for 30 days on the BIOLASE website.
BIOLASE is a leader in dental laser systems, developing innovative solutions with over 41,200 systems sold in 80+ countries.
BIOLASE, Inc. (NASDAQ: BIOL) announced the expiration of its oversubscribed rights offering on July 15, 2020. Initial plans for 15,000 units were increased to 18,000 due to strong demand. The offering raised approximately $18.0 million in gross proceeds, excluding potential future warrant exercises. Each unit consisted of one share of Series F Convertible Preferred Stock, convertible into common stock at $0.40, and included 2,500 warrants at the same exercise price. The closing is anticipated around July 20, 2020.
BIOLASE, a leader in dental lasers, announced that CEO Todd Norbe will participate in a webinar on July 16, 2020, focusing on re-engaging medical practices post-COVID-19. The webinar, hosted by Maxim Group and M-Vest, will address key concerns such as the reopening of medical practices, revenue recovery, and commercialization strategies. BIOLASE's innovative laser systems, supported by significant patented technologies, enhance dental procedures and have been sold in over 80 countries, with 41,200 systems deployed to date.
BIOLASE, Inc. (NASDAQ: BIOL) has announced the commencement of its rights offering subscription period as of July 2, 2020. Record holders wishing to participate must submit a completed subscription rights statement and payment by 5:00 PM Eastern Time on July 15, 2020. Each subscription right allows the purchase of one unit at $1,000, which includes new Series F Convertible Preferred Stock convertible into common stock at $0.40 per share, along with 2,500 warrants also at $0.40 per share. The company has engaged Maxim Group LLC and others as joint dealer-managers for the offering.
BIOLASE, Inc. (NASDAQ: BIOL) announced details about its proposed rights offering aimed at stockholders of record as of July 1, 2020. Each stockholder will receive a non-transferable subscription right to purchase units at $1,000, including newly created Series F Convertible Preferred Stock and warrants. The subscription period is from July 2 to July 15, 2020. BIOLASE plans to utilize the proceeds for working capital following strong recovery signals in the U.S. dental market, signaling a positive trend for dental practices amid COVID-19.